Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients

Kidney International

Volumn 70, Issue SUPPL. 103, 2006, Pages

  Axelsson, J ^a,b   Devuyst, O ^c   Nordfors, L ^b   Heimburger O ^a   Stenvinkel, P ^a,b   Lindholm, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

CKD; Clinical research; ESRD; Mendelian randomization; Peritoneal transport; Polymorphism; Translational research

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENOMIC DNA; HOMOCYSTEINE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PENTOSIDINE;

ATHEROSCLEROSIS; BIOINFORMATICS; BLOOD PRESSURE MONITORING; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HUMAN GENOME; INFECTIOUS COMPLICATION; KIDNEY FAILURE; MALNUTRITION; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PERITONITIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; ULTRAFILTRATION; CHRONIC KIDNEY FAILURE; GENETICS;

GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; LINKAGE (GENETICS); PERITONEAL DIALYSIS; PHENOTYPE;

EID: 39049187200     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001931     Document Type: Article

References (52)

1. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
2. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
3. Altshuler D, Brooks LD, Chakravarti A et al. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
4. Hinds DA, Stuve LL, Nilsen GB et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307: 1072-1079.
5. Reich DE, Gabriel SB, Altshuler D. Quality and completeness of SNP databases. Nat Genet 2003; 33: 457-458.
6. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004; 33: 30-42.
7. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat Genet 2003; 33(Suppl): 228-237.
8. Mi H, Lazareva-Ulitsky B, Loo R et al. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acid Res 2005; 33: D284-D288.
9. Reumers J, Schymkowitz J, Ferkinghoff-Borg J et al. SNPeffect: a database mapping molecular phenotypic effects of human non-synonymous coding SNPs. Nucleic Acid Res 2005; 33: D527-D532.
10. Yao Q, Axelsson J, Nordfors L et al. Peroxisome proliferator-activated receptor gamma polymorphisms in relation to inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Atherosclerosis 2005; 182: 105-111.
11. Persu A, Vinck WJ, El Khattabi O et al. Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: sib-pair analysis and haplotype study. J Hypertens 2005; 23: 759-765.
12. Avi-Itzhak HI, Su X, De La Vega FM. Selection of minimum subsets of single nucleotide polymorphisms to capture haplotype block diversity. Pac Symp Biocomput 2003: 466-477.
13. Cervino AC, Li G, Edwards S et al. Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics 2005; 86: 505-517.
14. Halldorsson BV, Istrail S, De La Vega FM. Optimal selection of SNP markers for disease association studies. Hum Hered 2004; 58: 190-202.
15. Stenvinkel P, Wang K, Qureshi AR et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392.
16. Emahazion T, Feuk L, Jobs M et al. SNP association studies in Alzheimer's disease highlight problems for complex disease analysis. Trends Genet 2001; 17: 407-413.
17. Heidema GA, Boer JM, Nagelkerke N et al. The challenge for genetic epidemiologists: how to analyze large numbers of SNPs in relation to complex diseases. BMC Genet 2006; 7: 23.
18. Pecoits-Filho R, Nordfors L, Lindholm B et al. Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation and atherosclerosis (MIA) as a prototype. Kidney Int 2003; 84: 162-167.
19. Churchill DN, Thorpe KE, Nolph KD et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998; 9: 1285-1292.
20. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 2006; 17: 271-278.
21. Margetts PJ, McMullin JP, Rabbat CG et al. Peritoneal membrane transport and hypoalbuminemia: cause or effect? Perit Dial Int 2000; 20: 14-18.
22. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66: 2437-2445.
23. Rumpsfeld M, McDonald SP, Purdie DM et al. Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am J Kidney Dis 2004; 43: 492-501.
24. Gillerot G, Goffin E, Michel C et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67: 2477-2487.
25. Rippe B, Simonsen O, Stelin G. Clinical implications of a three-pore model of peritoneal transport. Adv Perit Dial 1991; 7: 3-9.
26. Combet S, Ferrier ML, Van Landschoot M et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12: 2146-2157.
27. Margetts PJ, Gyorffy S, Kolb M et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13: 721-728.
28. Flessner M. Water-only pores and peritoneal dialysis. Kidney Int 2006; 69: 1494-1495.
29. Wong TY, Szeto CC, Szeto CY et al. Association of ENOS polymorphism with basal peritoneal membrane function in uremic patients. Am J Kidney Dis 2003; 42: 781-786.
30. Szeto CC, Chow KM, Poon P et al. Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 2004; 65: 1947-1955.
31. Gillerot G, Debaix H, Devuyst O. Genotyping: a new application for the spent dialysate in peritoneal dialysis. Nephrol Dial Transplant 2004; 19: 1298-1301.
32. Ni J, Moulin P, Gianello P et al. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 2003; 14: 3205-3216.
33. Dahmer MK, Randolph A, Vitali S et al. Genetic polymorphisms in sepsis. Pediatr Crit Care Med 2005; 6: S61-S73.
34. Bergström J, Lindholm B. Malnutrition, cardiac disease and mortality - an integrated point of view. Am J Kidney Dis 1998; 32: 834-841.
35. Heimburger O, Lonnqvist F, Danielsson A et al. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8: 1423-1430.
36. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115: 1659-1665.
37. Szeto CC, Poon P, Szeto CY et al. Plasminogen activator inhibitor-1 4G/5G genetic polymorphism does not affect peritoneal transport characteristic. Am J Kidney Dis 2002; 39: 1061-1067.
38. Zoccali F, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
39. Hara K, Boutin P, Mori Y et al. Genetic variations i the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002; 51: 536-540.
40. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281.
41. Iseki K, Tozawa M, Yoshi S et al. Serum C-reactive (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transpl 1999; 14: 1956-1960.
42. Stenvinkel P. Inflammation in end-stage renal disease - a fire that burns within. Contrib Nephrol 2005; 149: 185-199.
43. Liu Y, Berthier-Schaad Y, Fallin MD et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006; 17: 863-870.
44. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604.
45. Girndt M, Kaul H, Sester U et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949-955.
46. Ilveskoski E, Perola M, Lehtimaki T et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999; 100: 608-613.
47. Eggertsen G, Heimburger O, Stenvinkel P et al. Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. Nephrol Dial Transplant 1997; 12: 141-144.
48. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-2748.
49. Suliman ME, Qureshi AR, Barany P et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727-1735.
50. Wrone EM, Zehnder JL, Hornberger JM et al. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60: 1106-1113.
51. Piedrafita FJ, Molander RB, Vansant G et al. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996; 271: 14412-14420.
52. Pecoits-Filho R, Stenvinkel P, Marchlewska A et al. A functional variant in the myeloperoxidase (MPO) gene is associated with cardiovascular disease (CVD) in end-stage renal disease (ESRD) patients. Kidney Int 2003; 84: 172-176.